AMPH Quote, Financials, Valuation and Earnings

CorMedix, Inc. has a net margin of 9.04% compared to Amphastar Pharmaceuticals, Inc.'s net margin of 49.9%. Amphastar Pharmaceuticals, Inc.'s return on equity of 14.9% beat CorMedix, Inc.'s return on equity of 95.25%.

Amphastar Pharmaceuticals, Inc. has a consensus price target of $31.71, signalling upside risk potential of 17.46%. On the other hand CorMedix, Inc. has an analysts' consensus of $19.00 which suggests that it could grow by 52.24%. Given that CorMedix, Inc. has higher upside potential than Amphastar Pharmaceuticals, Inc., analysts believe CorMedix, Inc. is more attractive than Amphastar Pharmaceuticals, Inc..

Amphastar Pharmaceuticals, Inc. has a beta of 0.913, which suggesting that the stock is 8.747% less volatile than S&P 500. In comparison CorMedix, Inc. has a beta of 1.322, suggesting its more volatile than the S&P 500 by 32.155%.

Amphastar Pharmaceuticals, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. CorMedix, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Amphastar Pharmaceuticals, Inc. pays -- of its earnings as a dividend. CorMedix, Inc. pays out -- of its earnings as a dividend.

Amphastar Pharmaceuticals, Inc. quarterly revenues are $191.8M, which are larger than CorMedix, Inc. quarterly revenues of $104.3M. Amphastar Pharmaceuticals, Inc.'s net income of $17.4M is lower than CorMedix, Inc.'s net income of $108.6M. Notably, Amphastar Pharmaceuticals, Inc.'s price-to-earnings ratio is 11.97x while CorMedix, Inc.'s PE ratio is 6.08x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Amphastar Pharmaceuticals, Inc. is 1.84x versus 4.20x for CorMedix, Inc.. Usually stocks with elevated PS ratios are considered overvalued.

Ionis Pharmaceuticals, Inc. has a net margin of 9.04% compared to Amphastar Pharmaceuticals, Inc.'s net margin of -82.06%. Amphastar Pharmaceuticals, Inc.'s return on equity of 14.9% beat Ionis Pharmaceuticals, Inc.'s return on equity of -43.01%.

Amphastar Pharmaceuticals, Inc. has a consensus price target of $31.71, signalling upside risk potential of 17.46%. On the other hand Ionis Pharmaceuticals, Inc. has an analysts' consensus of $87.99 which suggests that it could grow by 11.42%. Given that Amphastar Pharmaceuticals, Inc. has higher upside potential than Ionis Pharmaceuticals, Inc., analysts believe Amphastar Pharmaceuticals, Inc. is more attractive than Ionis Pharmaceuticals, Inc..

Amphastar Pharmaceuticals, Inc. has a beta of 0.913, which suggesting that the stock is 8.747% less volatile than S&P 500. In comparison Ionis Pharmaceuticals, Inc. has a beta of 0.296, suggesting its less volatile than the S&P 500 by 70.45%.

Amphastar Pharmaceuticals, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Ionis Pharmaceuticals, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Amphastar Pharmaceuticals, Inc. pays -- of its earnings as a dividend. Ionis Pharmaceuticals, Inc. pays out -- of its earnings as a dividend.

Amphastar Pharmaceuticals, Inc. quarterly revenues are $191.8M, which are larger than Ionis Pharmaceuticals, Inc. quarterly revenues of $156.7M. Amphastar Pharmaceuticals, Inc.'s net income of $17.4M is higher than Ionis Pharmaceuticals, Inc.'s net income of -$128.6M. Notably, Amphastar Pharmaceuticals, Inc.'s price-to-earnings ratio is 11.97x while Ionis Pharmaceuticals, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Amphastar Pharmaceuticals, Inc. is 1.84x versus 13.45x for Ionis Pharmaceuticals, Inc.. Usually stocks with elevated PS ratios are considered overvalued.

Eli Lilly & Co. has a net margin of 9.04% compared to Amphastar Pharmaceuticals, Inc.'s net margin of 31.72%. Amphastar Pharmaceuticals, Inc.'s return on equity of 14.9% beat Eli Lilly & Co.'s return on equity of 106.26%.

Amphastar Pharmaceuticals, Inc. has a consensus price target of $31.71, signalling upside risk potential of 17.46%. On the other hand Eli Lilly & Co. has an analysts' consensus of $1,093.22 which suggests that it could grow by 1.25%. Given that Amphastar Pharmaceuticals, Inc. has higher upside potential than Eli Lilly & Co., analysts believe Amphastar Pharmaceuticals, Inc. is more attractive than Eli Lilly & Co..

Amphastar Pharmaceuticals, Inc. has a beta of 0.913, which suggesting that the stock is 8.747% less volatile than S&P 500. In comparison Eli Lilly & Co. has a beta of 0.370, suggesting its less volatile than the S&P 500 by 62.965%.

Amphastar Pharmaceuticals, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Eli Lilly & Co. offers a yield of 0.56% to investors and pays a quarterly dividend of $1.50 per share. Amphastar Pharmaceuticals, Inc. pays -- of its earnings as a dividend. Eli Lilly & Co. pays out 44.39% of its earnings as a dividend. Eli Lilly & Co.'s payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.

Amphastar Pharmaceuticals, Inc. quarterly revenues are $191.8M, which are smaller than Eli Lilly & Co. quarterly revenues of $17.6B. Amphastar Pharmaceuticals, Inc.'s net income of $17.4M is lower than Eli Lilly & Co.'s net income of $5.6B. Notably, Amphastar Pharmaceuticals, Inc.'s price-to-earnings ratio is 11.97x while Eli Lilly & Co.'s PE ratio is 53.40x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Amphastar Pharmaceuticals, Inc. is 1.84x versus 16.57x for Eli Lilly & Co.. Usually stocks with elevated PS ratios are considered overvalued.

Supernus Pharmaceuticals, Inc. has a net margin of 9.04% compared to Amphastar Pharmaceuticals, Inc.'s net margin of -23.49%. Amphastar Pharmaceuticals, Inc.'s return on equity of 14.9% beat Supernus Pharmaceuticals, Inc.'s return on equity of -1.84%.

Amphastar Pharmaceuticals, Inc. has a consensus price target of $31.71, signalling upside risk potential of 17.46%. On the other hand Supernus Pharmaceuticals, Inc. has an analysts' consensus of $61.33 which suggests that it could grow by 22.94%. Given that Supernus Pharmaceuticals, Inc. has higher upside potential than Amphastar Pharmaceuticals, Inc., analysts believe Supernus Pharmaceuticals, Inc. is more attractive than Amphastar Pharmaceuticals, Inc..

Amphastar Pharmaceuticals, Inc. has a beta of 0.913, which suggesting that the stock is 8.747% less volatile than S&P 500. In comparison Supernus Pharmaceuticals, Inc. has a beta of 0.715, suggesting its less volatile than the S&P 500 by 28.462%.

Amphastar Pharmaceuticals, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Supernus Pharmaceuticals, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Amphastar Pharmaceuticals, Inc. pays -- of its earnings as a dividend. Supernus Pharmaceuticals, Inc. pays out -- of its earnings as a dividend.

Amphastar Pharmaceuticals, Inc. quarterly revenues are $191.8M, which are smaller than Supernus Pharmaceuticals, Inc. quarterly revenues of $192.1M. Amphastar Pharmaceuticals, Inc.'s net income of $17.4M is higher than Supernus Pharmaceuticals, Inc.'s net income of -$45.1M. Notably, Amphastar Pharmaceuticals, Inc.'s price-to-earnings ratio is 11.97x while Supernus Pharmaceuticals, Inc.'s PE ratio is 41.17x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Amphastar Pharmaceuticals, Inc. is 1.84x versus 4.13x for Supernus Pharmaceuticals, Inc.. Usually stocks with elevated PS ratios are considered overvalued.